AIM
GMAB icon

Aigen Investment Management’s Genmab GMAB Stock Holding History

Aigen Investment Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,292
Closed -$257K – 850
2024
Q4 		$257K Buy
+12,292
New +$270K 0.05% 526
2024
Q3 		– Sell
-10,053
Closed -$253K – 831
2024
Q2 		$253K Buy
+10,053
New +$285K 0.05% 538
2024
Q1 		– Sell
-35,889
Closed -$1.14M – 805
2023
Q4 		$1.14M Buy
+35,889
New +$1.13M 0.2% 133
2022
Q2 		– Sell
-8,126
Closed -$294K – 605
2022
Q1 		$294K Buy
+8,126
New +$279K 0.05% 375
2020
Q3 		– Sell
-30,506
Closed -$1.03M – 952
2020
Q2 		$1.03M Sell
30,506
-11,807
-28% -$322K 0.13% 252
2020
Q1 		$897K Buy
+42,313
New +$943K 0.12% 247

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aigen Investment Management's GMAB Position: Q1 2025 in Review

Aigen Investment Management sold out of Genmab (GMAB) in Q1 2025, closing a stake of 12,292 shares — an estimated $257K sold.

Aigen Investment Management first reported a position in GMAB in Q1 2020 and held it in 6 quarters. The position peaked at $1.14M in Q4 2023. 219 funds tracked by Wall St. Rank hold GMAB as of Q1 2025.

  • Aigen Investment Management reported no remaining Genmab position as of Q1 2025 after selling out during the quarter.
  • Aigen Investment Management sold 12,292 Genmab shares in Q1 2025, an estimated $257K.
  • Aigen Investment Management first reported a position in Genmab in Q1 2020 and held it in 6 quarters.
  • Aigen Investment Management's Genmab position peaked at $1.14M in Q4 2023.
  • 219 funds tracked by Wall St. Rank held Genmab as of Q1 2025.

Based on Aigen Investment Management's 13F filing for Q1 2025, filed 12 May 2025.